Literature DB >> 30399314

Design of Y2 Receptor Selective and Proteolytically Stable PYY3-36 Analogues.

Søren Østergaard, Jacob Kofoed, Johan F Paulsson, Kim Grimstrup Madsen, Rasmus Jorgensen, Birgitte S Wulff.   

Abstract

In recent years peptide YY (PYY) has attracted attention within the area of diabetes and obesity due to its involvement in food intake regulation and glucose homeostasis. It is well-known that PYY1-36 is rapidly cleaved by dipeptidyl peptidase-4 to the more Y2 receptor selective analogue PYY3-36, which is further cleaved to the inactive analogue PYY3-34. In order to improve the selectivity and proteolytic stability of the C-terminus, we synthesized several analogues incorporating N-methyl amino acids or β-homo amino acids and other non-natural amino acids. These were tested against all four NPY receptors, and highly potent and Y2 receptor selective analogues were identified by combining a tryptophan residue in position 30 with either N-methyl or β-homo arginine in position 35. We also identified an analogue with a MeGln34 substitution that surprisingly displayed high affinity toward all four receptors. In addition, these analogues displayed improved stability toward C-terminal proteolysis compared to native PYY3-36.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30399314     DOI: 10.1021/acs.jmedchem.8b01046

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.

Authors:  Brian P Cary; Marlies V Hager; Samuel H Gellman
Journal:  Chembiochem       Date:  2019-09-20       Impact factor: 3.164

Review 2.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

3.  Backbone Modifications of HLA-A2-Restricted Antigens Induce Diverse Binding and T Cell Activation Outcomes.

Authors:  Ruslan Gibadullin; Caleb J Randall; John Sidney; Alessandro Sette; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2021-04-21       Impact factor: 15.419

Review 4.  PYY, a Therapeutic Option for Type 2 Diabetes?

Authors:  Claudia Guida; Reshma Ramracheya
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2020-01-22

5.  Modified Peptide YY Molecule Attenuates the Activity of NPY/AgRP Neurons and Reduces Food Intake in Male Mice.

Authors:  Edward S Jones; Nicolas Nunn; Adam P Chambers; Søren Østergaard; Birgitte S Wulff; Simon M Luckman
Journal:  Endocrinology       Date:  2019-11-01       Impact factor: 4.736

6.  The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs.

Authors:  Søren Østergaard; Johan F Paulsson; Jacob Kofoed; Franziska Zosel; Jørgen Olsen; Claus Bekker Jeppesen; Jane Spetzler; Lars Ynddal; Luise Gram Schleiss; Berit Østergaard Christoffersen; Kirsten Raun; Ulrich Sensfuss; Flemming Seier Nielsen; Rasmus Jørgensen; Birgitte S Wulff
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

7.  Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors.

Authors:  Tingting Tang; Qiuxiang Tan; Shuo Han; Anne Diemar; Kristin Löbner; Hongyu Wang; Corinna Schüß; Victoria Behr; Karin Mörl; Mu Wang; Xiaojing Chu; Cuiying Yi; Max Keller; Jacob Kofoed; Steffen Reedtz-Runge; Anette Kaiser; Annette G Beck-Sickinger; Qiang Zhao; Beili Wu
Journal:  Sci Adv       Date:  2022-05-04       Impact factor: 14.957

8.  Rational Development of Stable PYY3-36 Peptide Y2 Receptor Agonists.

Authors:  Christian Poulsen; Marie Østergaard Pedersen; Per-Olof Wahlund; Annika Sjölander; Jens Kaalby Thomsen; Kilian W Conde-Frieboes; Johan F Paulsson; Birgitte S Wulff; Søren Østergaard
Journal:  Pharm Res       Date:  2021-07-16       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.